Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Widespread Increased Diffusivity Reveals Early Cortical Degeneration in Huntington Disease.

Sampedro F, Martínez-Horta S, Perez-Perez J, Horta-Barba A, Martin-Lahoz J, Alonso-Solís A, Corripio I, Gomez-Anson B, Kulisevsky J.

AJNR Am J Neuroradiol. 2019 Sep;40(9):1464-1468. doi: 10.3174/ajnr.A6168.

PMID:
31467235
2.

Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis.

Bioque M, Mas S, Costanzo MC, Cabrera B, Lobo A, González-Pinto A, Rodriguez-Toscano E, Corripio I, Vieta E, Baeza I, Ibáñez Á, Fraile MG, Cuesta MJ, Mezquida G, Lafuente A, Bernardo M; PEPs GROUP.

Eur Neuropsychopharmacol. 2019 Jun;29(6):786-794. doi: 10.1016/j.euroneuro.2019.04.005. Epub 2019 May 7.

PMID:
31076188
3.

Mobile Phone and Wearable Sensor-Based mHealth Approaches for Psychiatric Disorders and Symptoms: Systematic Review.

Seppälä J, De Vita I, Jämsä T, Miettunen J, Isohanni M, Rubinstein K, Feldman Y, Grasa E, Corripio I, Berdun J, D'Amico E; M-RESIST Group, Bulgheroni M.

JMIR Ment Health. 2019 Feb 20;6(2):e9819. doi: 10.2196/mental.9819. Review.

4.

Validation of a Spanish version of the Schizotypal Personality Questionnaire (SPQ): Psychometric characteristics and underlying factor structure derived from a healthy university student sample.

Rabella M, Grasa E, Trujols J, Gich I, Torrubia R, Corripio I, Pérez V, Riba J.

Actas Esp Psiquiatr. 2018 Sep;46(5):159-73. Epub 2018 Sep 1.

5.

Cognitive reserve as an outcome predictor: first-episode affective versus non-affective psychosis.

Amoretti S, Cabrera B, Torrent C, Mezquida G, Lobo A, González-Pinto A, Parellada M, Corripio I, Vieta E, de la Serna E, Butjosa A, Contreras F, Sarró S, Penadés R, Sánchez-Torres AM, Cuesta M, Bernardo M; PEPsGroup.

Acta Psychiatr Scand. 2018 Nov;138(5):441-455. doi: 10.1111/acps.12949. Epub 2018 Aug 14.

PMID:
30105820
6.

Mobile therapeutic attention for treatment-resistant schizophrenia (m-RESIST): a prospective multicentre feasibility study protocol in patients and their caregivers.

Alonso-Solís A, Rubinstein K, Corripio I, Jaaskelainen E, Seppälä A, Vella VA, Caro-Mendivelso J, Caspi A, Isohanni M, Unoka Z, Van der Graff S, Farkas K, Huerta-Ramos E, Marcó-García S, Stevens M, Coenen T, Hospedales M, Berdún J; m-Resist group, Grasa EM.

BMJ Open. 2018 Jul 16;8(7):e021346. doi: 10.1136/bmjopen-2017-021346.

7.

Affective versus non-affective first episode psychoses: A longitudinal study.

Torrent C, Reinares M, Martinez-Arán A, Cabrera B, Amoretti S, Corripio I, Contreras F, Sarró S, González-Pinto A, Lobo A, Cuesta MJ, Sánchez-Torres A, Bergé D, Castro-Fornieles J, Moreno C, Bernardo M, Vieta E; PEPS group.

J Affect Disord. 2018 Oct 1;238:297-304. doi: 10.1016/j.jad.2018.06.005. Epub 2018 Jun 4.

PMID:
29902733
8.

Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis.

Gassó P, Mas S, Bioque M, Cabrera B, Lobo A, González-Pinto A, Díaz-Caneja CM, Corripio I, Vieta E, Castro-Fornieles J, Sarró S, Mané A, Sanjuan J, Llerena A, Lafuente A, Saiz-Ruiz J, Bernardo M; PEPs Group.

J Psychopharmacol. 2018 Jun;32(6):702-710. doi: 10.1177/0269881118773026. Epub 2018 May 16.

PMID:
29767567
9.

Smoking does not impact social and non-social cognition in patients with first episode psychosis.

Sánchez-Gutiérrez T, García-Portilla MP, Parellada M, Bobes J, Calvo A, Moreno-Izco L, González-Pinto A, Lobo A, de la Serna E, Cabrera B, Torrent C, Roldán L, Sanjuan J, Ibáñez Á, Sánchez-Torres AM, Corripio I, Bernardo M, Cuesta MJ; PEPs group.

Schizophr Res. 2018 Sep;199:64-74. doi: 10.1016/j.schres.2018.03.025. Epub 2018 Mar 30.

PMID:
29606546
10.

Gray and white matter changes and their relation to illness trajectory in first episode psychosis.

Keymer-Gausset A, Alonso-Solís A, Corripio I, Sauras-Quetcuti RB, Pomarol-Clotet E, Canales-Rodriguez EJ, Grasa-Bello E, Álvarez E, Portella MJ.

Eur Neuropsychopharmacol. 2018 Mar;28(3):392-400. doi: 10.1016/j.euroneuro.2017.12.117. Epub 2018 Jan 12.

PMID:
29338891
11.

Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?

Ballesteros A, Sánchez-Torres AM, López-Ilundain JM, Cabrera B, Lobo A, González-Pinto AM, Díaz-Caneja C, Corripio I, Vieta E, de la Serna E, Bobes J, Usall J, Contreras F, Lorente-Omeñaca R, Mezquida G, Bernardo M, Cuesta MJ; PEPs Group.

Psychol Med. 2018 Oct;48(13):2247-2256. doi: 10.1017/S0033291717003774. Epub 2018 Jan 14.

PMID:
29331153
12.

m-RESIST, a complete m-Health solution for patients with treatmentresistant schizophrenia: a qualitative study of user needs and acceptability in the Barcelona metropolitan area.

Huerta-Ramos E, Marcó-García S, Escobar-Villegas MS, Rubio-Abadal E, Ochoa S, Grasa Bello EM, Alonso Solís A, Rabella M, Berdun J, Hospedales M, M-Resist G, Corripio I, Usall J.

Actas Esp Psiquiatr. 2017 Nov;45(6):277-89. Epub 2017 Nov 1.

13.

Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study.

Sánchez-Torres AM, Moreno-Izco L, Lorente-Omeñaca R, Cabrera B, Lobo A, González-Pinto AM, Merchán-Naranjo J, Corripio I, Vieta E, de la Serna E, Butjosa A, Contreras F, Sarró S, Mezquida G, Ribeiro M, Bernardo M, Cuesta MJ; PEPs group.

Eur Arch Psychiatry Clin Neurosci. 2018 Oct;268(7):699-711. doi: 10.1007/s00406-017-0857-z. Epub 2017 Nov 21.

PMID:
29164332
14.

Persistent Negative Symptoms in First-Episode Psychosis: Early Cognitive and Social Functioning Correlates and Differences Between Early and Adult Onset.

Puig O, Baeza I, de la Serna E, Cabrera B, Mezquida G, Bioque M, Lobo A, González-Pinto A, Parellada M, Corripio I, Vieta E, Bobes J, Usall J, Contreras F, Cuesta MJ, Bernardo M, Castro-Fornieles J; PEPs Group.

J Clin Psychiatry. 2017 Nov/Dec;78(9):1414-1422. doi: 10.4088/JCP.16m11122.

PMID:
28922588
15.

Volumetric and morphological characteristics of the hippocampus are associated with progression to schizophrenia in patients with first-episode psychosis.

Sauras R, Keymer A, Alonso-Solis A, Díaz A, Molins C, Nuñez F, Rabella M, Roldán A, Grasa E, Alvarez E, Portella MJ, Corripio I.

Eur Psychiatry. 2017 Sep;45:1-5. doi: 10.1016/j.eurpsy.2017.06.006. Epub 2017 Jul 5.

PMID:
28728089
16.

Emotional fMR auditory paradigm demonstrates normalization of limbic hyperactivity after cognitive behavior therapy for auditory hallucinations.

Aguilar EJ, Corripio I, García-Martí G, Grasa E, Martí-Bonmatí L, Gómez-Ansón B, Sanjuán J, Núñez-Marín F, Lorente-Rovira E, Escartí MJ, Brabban A, Turkington D.

Schizophr Res. 2018 Mar;193:304-312. doi: 10.1016/j.schres.2017.07.024. Epub 2017 Jul 15. No abstract available.

PMID:
28720416
17.

Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis.

Bioque M, García-Portilla MAP, García-Rizo C, Cabrera B, Lobo A, González-Pinto A, Díaz-Caneja CM, Corripio I, Vieta E, Castro-Fornieles J, Bobes J, Gutiérrez-Fraile M, Rodriguez-Jimenez R, Mezquida G, Llerena A, Saiz-Ruiz J, Bernardo M; PEPs GROUP.

Schizophr Res. 2018 Mar;193:188-196. doi: 10.1016/j.schres.2017.06.032. Epub 2017 Jun 26.

PMID:
28663026
18.

Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients.

Mas S, Gassó P, Torra M, Bioque M, Lobo A, González-Pinto A, Olmeda MS, Corripio I, Vieta E, Castro-Fornieles J, Rodriguez-Jimenez R, Bobes J, Usall J, Llerena A, Saiz-Ruiz J, Bernardo M, Lafuente A, PEPs Group.

Eur Neuropsychopharmacol. 2017 Jul;27(7):647-656. doi: 10.1016/j.euroneuro.2017.03.012. Epub 2017 Apr 5.

PMID:
28389049
19.

Gene-environment interaction as a predictor of early adjustment in first episode psychosis.

Fraguas D, Díaz-Caneja CM, Corripio I, González-Pinto A, Lobo A, Bioque M, Cuesta MJ, Sanjuán J, Rodríguez-Toscano E, Arias B, Sarró S, Cabrera B, Bulbena A, Vieta E, Castro-Fornieles J, Arango C, Bernardo M, Parellada M; PEPs group.

Schizophr Res. 2017 Nov;189:196-203. doi: 10.1016/j.schres.2017.02.021. Epub 2017 Mar 2.

PMID:
28262436
20.

The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study.

Mezquida G, Cabrera B, Bioque M, Amoretti S, Lobo A, González-Pinto A, Espliego A, Corripio I, Vieta E, Castro-Fornieles J, Bergé D, Escartí MJ, Ibañez Á, Penadés R, Sánchez-Torres AM, Bernardo M; PEPs Group.

Schizophr Res. 2017 Nov;189:84-90. doi: 10.1016/j.schres.2017.01.047. Epub 2017 Feb 6.

PMID:
28185786
21.

Modelling gene-environment interaction in first episodes of psychosis.

Bernardo M, Bioque M, Cabrera B, Lobo A, González-Pinto A, Pina L, Corripio I, Sanjuán J, Mané A, Castro-Fornieles J, Vieta E, Arango C, Mezquida G, Gassó P, Parellada M, Saiz-Ruiz J, Cuesta MJ, Mas S; PEPs GROUP.

Schizophr Res. 2017 Nov;189:181-189. doi: 10.1016/j.schres.2017.01.058. Epub 2017 Feb 5.

PMID:
28179063
22.

Randomized control trial to assess the efficacy of metacognitive training compared with a psycho-educational group in people with a recent-onset psychosis.

Ochoa S, López-Carrilero R, Barrigón ML, Pousa E, Barajas A, Lorente-Rovira E, González-Higueras F, Grasa E, Ruiz-Delgado I, Cid J, Birulés I, Esteban-Pinos I, Casañas R, Luengo A, Torres-Hernández P, Corripio I, Montes-Gámez M, Beltran M, De Apraiz A, Domínguez-Sánchez L, Sánchez E, Llacer B, Pélaez T, Bogas JL, Moritz S; Spanish Metacognition Study Group.

Psychol Med. 2017 Jul;47(9):1573-1584. doi: 10.1017/S0033291716003421. Epub 2017 Feb 7.

PMID:
28166848
23.

Cannabis use, COMT, BDNF and age at first-episode psychosis.

Mané A, Bergé D, Penzol MJ, Parellada M, Bioque M, Lobo A, González-Pinto A, Corripio I, Cabrera B, Sánchez-Torres AM, Saiz-Ruiz J, Bernardo M; PEPs Group.

Psychiatry Res. 2017 Apr;250:38-43. doi: 10.1016/j.psychres.2017.01.045. Epub 2017 Jan 19.

PMID:
28142064
24.

Altered amplitude of low frequency fluctuations in schizophrenia patients with persistent auditory verbal hallucinations.

Alonso-Solís A, Vives-Gilabert Y, Portella MJ, Rabella M, Grasa EM, Roldán A, Keymer-Gausset A, Molins C, Núñez-Marín F, Gómez-Ansón B, Alvarez E, Corripio I.

Schizophr Res. 2017 Nov;189:97-103. doi: 10.1016/j.schres.2017.01.042. Epub 2017 Jan 28.

PMID:
28139359
25.

Measuring Users' Receptivity Toward an Integral Intervention Model Based on mHealth Solutions for Patients With Treatment-Resistant Schizophrenia (m-RESIST): A Qualitative Study.

Huerta-Ramos E, Escobar-Villegas MS, Rubinstein K, Unoka ZS, Grasa E, Hospedales M, Jääskeläinen E, Rubio-Abadal E, Caspi A, Bitter I, Berdun J, Seppälä J, Ochoa S, Fazekas K; M-RESIST Group, Corripio I, Usall J.

JMIR Mhealth Uhealth. 2016 Sep 28;4(3):e112. doi: 10.2196/mhealth.5716.

26.

Association of the brain-derived neurotrophic factor Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders.

Mezquida G, Penadés R, Cabrera B, Savulich G, Lobo A, González-Pinto A, Penzol MJ, Corripio I, Fernandez-Egea E, Gassó P, Cuesta MJ, Bernardo M; PEPs group.

Eur Psychiatry. 2016 Oct;38:61-69. doi: 10.1016/j.eurpsy.2016.04.011. Epub 2016 Sep 24.

PMID:
27668551
27.

Response to antipsychotic drugs in treatment-resistant schizophrenia: Conclusions based on systematic review.

Molins C, Roldán A, Corripio I, Isohanni M, Miettunen J, Seppälä J, Seppälä A, Koponen H, Moilanen J, Jääskeläinen E; m-RESIST Group.

Schizophr Res. 2016 Dec;178(1-3):64-67. doi: 10.1016/j.schres.2016.09.016. Epub 2016 Sep 17. No abstract available.

PMID:
27650195
28.

Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History.

González-Pinto A, González-Ortega I, Alberich S, Ruiz de Azúa S, Bernardo M, Bioque M, Cabrera B, Corripio I, Arango C, Lobo A, Sánchez-Torres AM, Cuesta MJ; PEPs Group.

PLoS One. 2016 Aug 11;11(8):e0160949. doi: 10.1371/journal.pone.0160949. eCollection 2016.

29.

Neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder and its reversal by dopaminergic antagonism.

Rabella M, Grasa E, Corripio I, Romero S, Mañanas MÀ, Antonijoan RM, Münte TF, Pérez V, Riba J.

Neuroimage Clin. 2016 Jun 1;11:770-779. doi: 10.1016/j.nicl.2016.05.019. eCollection 2016.

30.

Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.

Mas S, Gassó P, Lafuente A, Bioque M, Lobo A, Gonzàlez-Pinto A, Olmeda MS, Corripio I, Llerena A, Cabrera B, Saiz-Ruiz J, Bernardo M; PEPs GROUP.

Pharmacogenomics J. 2016 Oct;16(5):439-45. doi: 10.1038/tpj.2016.44. Epub 2016 Jun 7.

PMID:
27272046
31.

Clinical Improvement in a Treatment-Resistant Patient With Schizophrenia Treated With Deep Brain Stimulation.

Corripio I, Sarró S, McKenna PJ, Molet J, Álvarez E, Pomarol-Clotet E, Portella MJ.

Biol Psychiatry. 2016 Oct 15;80(8):e69-70. doi: 10.1016/j.biopsych.2016.03.1049. Epub 2016 Mar 10. No abstract available.

PMID:
27113497
32.

Letter to the Editor: Deep brain stimulation for schizophrenia.

Salgado-López L, Pomarol-Clotet E, Roldán A, Rodríguez R, Molet J, Sarró S, Álvarez E, Corripio I.

J Neurosurg. 2016 Jul;125(1):229-30. doi: 10.3171/2015.12.JNS152874. Epub 2016 Apr 22. No abstract available.

PMID:
27104842
33.

Substance Use in Patients With First-Episode Psychosis: Is Gender Relevant?

Arranz B, Safont G, Corripio I, Ramirez N, Dueñas RM, Perez V, Alvarez E, San L.

J Dual Diagn. 2015;11(3-4):153-60. doi: 10.1080/15504263.2015.1113761.

PMID:
26513726
34.

A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project.

Bioque M, Llerena A, Cabrera B, Mezquida G, Lobo A, González-Pinto A, Díaz-Caneja CM, Corripio I, Aguilar EJ, Bulbena A, Castro-Fornieles J, Vieta E, Lafuente A, Mas S, Parellada M, Saiz-Ruiz J, Cuesta MJ, Bernardo M; PEPs GROUP.

Int J Neuropsychopharmacol. 2016 Mar 31;19(4). pii: pyv121. doi: 10.1093/ijnp/pyv121. Print 2016 Apr.

35.

Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study.

Cuesta MJ, Sánchez-Torres AM, Cabrera B, Bioque M, Merchán-Naranjo J, Corripio I, González-Pinto A, Lobo A, Bombín I, de la Serna E, Sanjuan J, Parellada M, Saiz-Ruiz J, Bernardo M; PEPs Group.

Schizophr Res. 2015 May;164(1-3):65-73. doi: 10.1016/j.schres.2015.02.022. Epub 2015 Mar 26.

PMID:
25819935
36.

Resting-state functional connectivity alterations in the default network of schizophrenia patients with persistent auditory verbal hallucinations.

Alonso-Solís A, Vives-Gilabert Y, Grasa E, Portella MJ, Rabella M, Sauras RB, Roldán A, Núñez-Marín F, Gómez-Ansón B, Pérez V, Alvarez E, Corripio I.

Schizophr Res. 2015 Feb;161(2-3):261-8. doi: 10.1016/j.schres.2014.10.047. Epub 2014 Nov 20.

PMID:
25468173
37.

Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): rationale, objectives, design and sample description.

Pina-Camacho L, Díaz-Caneja CM, Saiz PA, Bobes J, Corripio I, Grasa E, Rodriguez-Jimenez R, Fernández M, Sanjuán J, García-López A, Tapia-Casellas C, Álvarez-Blázquez M, Fraguas D, Mitjans M, Arias B, Arango C.

Rev Psiquiatr Salud Ment. 2014 Oct-Dec;7(4):166-78. doi: 10.1016/j.rpsm.2014.05.004. Epub 2014 Oct 19. English, Spanish.

PMID:
25440735
38.

Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.

Usall J, López-Carrilero R, Iniesta R, Roca M, Caballero M, Rodriguez-Jimenez R, Oliveira C, Bernardo M, Corripio I, Sindreu SD, González Piqueras JC, Felipe AE, Fernandez de Corres B, Ibáñez A, Huerta R; Abordaje Síntomas Negativos Esquizofrenia Group.

J Clin Psychiatry. 2014 Jun;75(6):608-15. doi: 10.4088/JCP.13m08551.

PMID:
25004184
39.

One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.

San L, Arranz B, Perez V, Safont G, Corripio I, Ramirez N, Dueñas R, Alvarez E.

Psychiatry Res. 2012 Dec 30;200(2-3):693-701. doi: 10.1016/j.psychres.2012.07.005. Epub 2012 Sep 3.

PMID:
22954905
40.

Altered default network resting state functional connectivity in patients with a first episode of psychosis.

Alonso-Solís A, Corripio I, de Castro-Manglano P, Duran-Sindreu S, Garcia-Garcia M, Proal E, Nuñez-Marín F, Soutullo C, Alvarez E, Gómez-Ansón B, Kelly C, Castellanos FX.

Schizophr Res. 2012 Aug;139(1-3):13-8. doi: 10.1016/j.schres.2012.05.005. Epub 2012 May 26.

41.

The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: iodine-123-iodobenzamide single photon emission computed tomography study.

Corripio I, Ferreira A, Portella MJ, Pérez V, Escartí MJ, Del Valle Camacho M, Sauras RB, Alonso A, Grasa EM, Carrió I, Catafau AM, Alvarez E.

Psychiatry Res. 2012 Jan 30;201(1):73-7. doi: 10.1016/j.pscychresns.2011.02.004. Epub 2012 Jan 26.

PMID:
22281201
42.

Density of striatal D2 receptors in untreated first-episode psychosis: an I123-IBZM SPECT study.

Corripio I, Escartí MJ, Portella MJ, Pérez V, Grasa E, Sauras RB, Alonso A, Safont G, Camacho MV, Dueñas R, Arranz B, San L, Catafau AM, Carrió I, Alvarez E.

Eur Neuropsychopharmacol. 2011 Dec;21(12):861-6. doi: 10.1016/j.euroneuro.2011.03.004. Epub 2011 Apr 5.

PMID:
21470832
43.

Cannabis use and striatal D2 receptor density in untreated first-episode psychosis: an in vivo SPECT study.

Safont G, Corripio I, Escartí MJ, Portella MJ, Pérez V, Ferrer M, Camacho V, Sauras RB, Alonso A, Grasa EM, Arranz B, San L, Dueñas R, Carrió I, Álvarez E.

Schizophr Res. 2011 Jul;129(2-3):169-71. doi: 10.1016/j.schres.2011.03.012. Epub 2011 Apr 2.

PMID:
21459559
44.

[Diagnostic of intestinal parasitosis by coproantigen detection].

Corripio IF, Cisneros MJ, Ormaechea TG.

Enferm Infecc Microbiol Clin. 2010 Jan;28 Suppl 1:33-9. doi: 10.1016/S0213-005X(10)70006-9. Review. Spanish.

PMID:
20172421
45.

Predictors of schizophrenia in patients with a first episode of psychosis.

Ramirez N, Arranz B, Salavert J, Alvarez E, Corripio I, Dueñas RM, Perez V, San L.

Psychiatry Res. 2010 Jan 30;175(1-2):11-4. doi: 10.1016/j.psychres.2009.03.013.

PMID:
19923008
46.

Clinical and serotonergic predictors of non-affective acute remitting psychosis in patients with a first-episode psychosis.

Arranz B, San L, Ramírez N, Dueñas RM, Perez V, Salavert J, Corripio I, Alvarez E.

Acta Psychiatr Scand. 2009 Jan;119(1):71-7. doi: 10.1111/j.1600-0447.2008.01253.x. Epub 2008 Aug 29.

PMID:
18764839
47.

Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients.

Catafau AM, Penengo MM, Nucci G, Bullich S, Corripio I, Parellada E, García-Ribera C, Gomeni R, Merlo-Pich E; Barcelona Clinical Imaging in Psychiatry Group.

J Psychopharmacol. 2008 Nov;22(8):882-94. doi: 10.1177/0269881107083810. Epub 2008 Feb 28.

PMID:
18308793
48.

[Autochthonous amebic liver abscess: microbiological diagnosis by PCR].

Gutiérrez-Cisneros MJ, Padín ES, Ormaechea TG, Corripio IF.

Enferm Infecc Microbiol Clin. 2007 Aug-Sep;25(7):493-4. Spanish. No abstract available.

PMID:
17692221
49.

Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response.

Catafau AM, Corripio I, Pérez V, Martin JC, Schotte A, Carrió I, Alvarez E.

Psychiatry Res. 2006 Dec 1;148(2-3):175-83. Epub 2006 Oct 23.

PMID:
17059881
50.

Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study.

Catafau AM, Perez V, Plaza P, Pascual JC, Bullich S, Suarez M, Penengo MM, Corripio I, Puigdemont D, Danus M, Perich J, Alvarez E.

Psychopharmacology (Berl). 2006 Dec;189(2):145-53. Epub 2006 Oct 11.

PMID:
17033844

Supplemental Content

Loading ...
Support Center